Comparison · NCT03841773-sae
TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events. Trial comparisons, record NCT03841773-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03841773-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0.00000000000000000347 | 0.0385 | wilson | |
| Risk in group 2 | 0.022 | 0.00605 | 0.0766 | wilson | |
| Risk difference, group 1 minus group 2 | -0.022 | -0.0766 | 0.0197 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on TNX-102 SL Tablet, 5.6 mg than on Placebo SL Tablet | 45.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TNX-102 SL Tablet, 5.6 mg | 2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.~TNX-102 SL: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks | 0 | 96 | EG001 |
| Group 2 | Placebo SL Tablet | 2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.~Placebo SL Tablets: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks | 2 | 91 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 14 weeks
Source ClinicalTrials.gov
Trial
- Title
- A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
- NCT number
- NCT03841773
- Phases
- PHASE3
- Conditions
- PTSD
- Interventions
- TNX-102 SL, Placebo SL Tablets
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Results first posted
- 2025-02-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03841773?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03841773-sae